| Literature DB >> 34277026 |
Amal A El-Masry1, Dalia R El-Wasseef1,2, Manal Eid3, Ihsan A Shehata1, Abdallah M Zeid3.
Abstract
A facile, rapid, accurate and selective quantitative proton nuclear magnetic resonance (1H-qNMR) method was developed for the simultaneous determination of fluticasone propionate (FLP) and azelastine hydrochloride (AZH) in pharmaceutical nasal spray for the first time. The 1H-qNMR analysis of the studied analytes was performed using inositol as the internal standard and dimethyl sulfoxide-d6 (DMSO-d6) as the solvent. The quantitative selective proton signal of FLP was doublet of doublet at 6.290, 6.294, 6.316 and 6.319 ppm, while that of AZH was doublet at 8.292 and 8.310 ppm. The internal standard (inositol) produced a doublet signal at 3.70 and 3.71 ppm. The method was rectilinear over the concentration ranges of 0.25-20.0 and 0.2-15.0 mg ml-1 for FLP and AZH, respectively. No labelling or pretreatment steps were required for NMR analysis of the studied analytes. The proposed 1H-qNMR method was validated efficiently according to the International Council on Harmonisation guidelines in terms of linearity, limit of detection, limit of quantification, accuracy, precision, specificity and stability. Moreover, the method was applied to assay the analytes in their combined nasal spray formulation. The results ensured the linearity (r 2 > 0.999), precision (% RSD < 1.5), stability, specificity and selectivity of the developed method.Entities:
Keywords: 1H-qNMR; azelastine hydrochloride; fluticasone propionate; nasal spray formulation
Year: 2021 PMID: 34277026 PMCID: PMC8278066 DOI: 10.1098/rsos.210483
Source DB: PubMed Journal: R Soc Open Sci ISSN: 2054-5703 Impact factor: 2.963
Figure 1Chemical structure of the studied analytes and the internal standard.
Figure 21H-NMR spectra of (a) inositol NF 12, (b) azelastine HCl (AZH), (c) fluticasone propionate (FLP) and (d) a mixture of AZH and FLP (containing inositol NF 12 as internal standard), in dimethylsulfoxide-d (DMSO- d6) under the optimum acquisition and elaboration conditions.
Figure 3Influence of (a) number of scans, (b) pulse angle and (c) relaxation delay time, on the absolute integral area of the selected signals of FLP and AZH in 1H-NMR spectra.
Performance data for the determination of the FLP and AZH through the laboratory-performed 1H-qNMR method.
| parameter | FLP | AZH |
|---|---|---|
| concentration range (mg ml−1) | 0.25–20.0 | 0.20–15.0 |
| correlation coefficient | 0.9999 | 0.9999 |
| slope | 0.02 | 0.03 |
| intercept | 64 × 10−4 | 1 × 10−4 |
| LOD (mg ml−1) | 0.04 | 0.02 |
| LOQ (mg ml−1) | 0.12 | 0.05 |
| 43 × 10−5 | 27 × 10−5 | |
| 21 × 10−5 | 13 × 10−5 | |
| 2 × 10−5 | 2 × 10−5 | |
| % RSD | 0.91 | 1.04 |
| % error = (s.d./√ | 0.32 | 0.37 |
Comparative analytical data for determination of FLP and AZH in pure form by the proposed 1H-qNMR method and comparison HPLC method.
| drug | proposed 1H-qNMR method | comparison HPLC method [ | ||
|---|---|---|---|---|
| amount taken (mg ml−1) | amount found (mg ml−1) | % recoverya | % recoverya | |
| FLP | 0.25 | 0.25 | 98.80 | 100.19 |
| 0.30 | 0.30 | 100.33 | 99.26 | |
| 0.80 | 0.82 | 102.00 | 101.71 | |
| 1.00 | 1.00 | 100.10 | 99.65 | |
| 5.00 | 4.98 | 99.52 | ||
| 10.00 | 10.04 | 100.36 | ||
| 15.00 | 14.98 | 99.84 | ||
| 20.00 | 20.04 | 100.18 | ||
| 100.14 ± 0.91 | 100.20 ± 1.08 | |||
| 0.1 (2.23)b | ||||
| 1.39 (8.89)b | ||||
| AZH | 0.20 | 0.20 | 98.50 | 98.84 |
| 0.30 | 0.29 | 98.00 | 99.13 | |
| 0.80 | 0.81 | 101.38 | 101.04 | |
| 1.00 | 1.00 | 99.60 | 99.43 | |
| 5.00 | 4.99 | 99.78 | ||
| 8.00 | 8.01 | 100.18 | ||
| 10.00 | 10.00 | 99.96 | ||
| 15.00 | 14.99 | 99.95 | ||
| 99.67 ± 1.04 | 99.61 ± 0.98 | |||
| 0.09 (2.23)b | ||||
| 1.11 (8.89)b | ||||
aEach result is the mean recovery of three separate determinations.
bFigures between brackets are the tabulated t- and F-values at p = 0.05.
Intra-day and inter-day precision data for the assay of FLP and AZH by the proposed 1H-qNMR method.
| parameters | FLP concentration (mg ml−1) | AZH concentration (mg ml−1) | |||||
|---|---|---|---|---|---|---|---|
| 1.0 | 5.0 | 10.0 | 1.0 | 5.0 | 10.0 | ||
| intra-day | % founda | 101.27 | 100.12 | 101.57 | 99.64 | 100.29 | 98.53 |
| 100.06 | 99.52 | 100.36 | 100.36 | 99.78 | 99.96 | ||
| 101.22 | 100.00 | 100.96 | 100.72 | 99.28 | 99.25 | ||
| 100.85 | 99.88 | 100.96 | 100.24 | 99.78 | 99.25 | ||
| ±s.d. | 0.68 | 0.32 | 0.60 | 0.55 | 0.50 | 0.72 | |
| % RSD | 0.68 | 0.32 | 0.60 | 0.55 | 0.50 | 0.72 | |
| % error | 0.39 | 0.18 | 0.34 | 0.32 | 0.29 | 0.42 | |
| inter-day | % founda | 101.08 | 100.48 | 100.96 | 98.57 | 100.29 | 98.53 |
| 100.06 | 99.52 | 100.36 | 100.36 | 99.78 | 99.96 | ||
| 99.46 | 99.76 | 99.16 | 99.64 | 98.04 | 100.39 | ||
| 100.20 | 99.92 | 100.16 | 99.52 | 99.37 | 99.63 | ||
| ±s.d. | 0.82 | 0.50 | 0.92 | 0.90 | 1.20 | 0.98 | |
| % RSD | 0.82 | 0.50 | 0.92 | 0.90 | 1.20 | 0.98 | |
| % error | 0.47 | 0.29 | 0.53 | 0.52 | 0.69 | 0.57 | |
aEach result is the mean recovery of three individual determinations.
Sample stability data for the assay of FLP and AZH by the proposed 1H-qNMR method.
| time (hour) | per cent assay of the sample solution | |
|---|---|---|
| FLP (%) | AZH (%) | |
| 0 | 100.36 | 99.96 |
| 6 | 100.42 | 99.86 |
| 12 | 100.30 | 99.57 |
| 24 | 100.06 | 99.93 |
| mean ( | 100.29 | 99.83 |
| RSD % | 0.16 | 0.18 |
Figure 41H-NMR spectrum of fluticasone propionate (FLP) and azelastine hydrochloride (AZH) in their laboratory synthetic mixture using inositol NF 12 as the internal standard (IS) and dimethylsulfoxide-d6 (DMSO-d6) as the solvent.
Figure 51H-NMR spectrum of fluticasone propionate (FLP) and azelastine hydrochloride (AZH) in Dymista® nasal spray using inositol NF 12 as the internal standard (IS) and dimethyl sulfoxide-d6 (DMSO-d6) as the solvent.
Comparative resultant data from simultaneous determination of FLP and AZH in their laboratory-prepared mixture by the proposed 1H-qNMR and comparison HPLC method.
| drug | proposed 1H-qNMR method | comparison HPLC method [ | ||
|---|---|---|---|---|
| amount taken (mg ml−1) | amount found (mg ml−1) | % recoverya | % recoverya | |
| FLP | 0.37 | 0.37 | 100.84 | 99.99 |
| 1.83 | 1.80 | 98.70 | 102.37 | |
| 2.92 | 2.90 | 99.23 | 101.62 | |
| 99.59 ± 1.12 | 101.33 ± 1.22 | |||
| 1.82 (2.78)b | ||||
| 1.19 (19)b | ||||
| AZH | 1.00 | 1.00 | 100.36 | 99.89 |
| 5.00 | 4.99 | 99.78 | 100.33 | |
| 8.00 | 7.95 | 99.37 | 101.43 | |
| 99.84 ± 0.50 | 100.55 ± 0.79 | |||
| 1.32 (2.78)b | ||||
| 2.54 (19)b | ||||
aEach result is the mean recovery of three separate determinations.
bFigures between brackets are the tabulated t- and F-values at p = 0.05.
Comparative resulting data from simultaneous determination of FLP and AZH in their pharmaceutical nasal spray suspension by the proposed 1H-qNMR and comparison HPLC method.
| drug | proposed 1H-qNMR method | comparison HPLC method [ | ||||||
|---|---|---|---|---|---|---|---|---|
| amount taken (mg ml−1) | amount found (mg ml−1) | % recoveryb | % recoveryb | |||||
| Dymista® nasal spraya FLP/AZH | FLP | AZH | FLP | AZH | FLP | AZH | FLP | AZH |
| 0.40 | 1.096 | 0.39 | 1.11 | 98.64 | 100.98 | 99.16 | 99.96 | |
| 0.60 | 1.644 | 0.60 | 1.63 | 100.63 | 98.98 | 98.82 | 100.13 | |
| 0.80 | 2.192 | 0.79 | 2.18 | 98.34 | 99.42 | 100.89 | 101.75 | |
| FLP | AZH | |||||||
| 99.21 ± 1.24 | 99.79 ± 1.05 | 99.62 ± 1.11 | 100.61 ± 0.99 | |||||
| 0.44 (2.78)c | 0.99 (2.78)c | |||||||
| 1.26 (19)c | 1.13 (19)c | |||||||
aDymista nasal spray suspension; labelled to contain 50 µg FLP and 137 µg AZH per each spray, Batch no # 546, manufactured by Cipla Ltd, India, M.L. for Meda Pharmaceuticals Inc. Somerset, NJ.
bEach result is the mean recovery of three separate determinations.
cFigures between brackets are the tabulated t- and F-values at p = 0.05.